Genprex rises as diabetes gene therapy shows promise in animal tests

Shares of drug developer Genprex GNPX.O rise 7.8% to $1.94 premarket

Co says its experimental gene therapy for diabetes, GPX-002, showed encouraging results in early animal studies

Says therapy improved sugar processing; one primate in study normalized blood sugar after 7 months, another showed improvement but did not fully normalize sugar levels

Mice normalized within 4 weeks - GNPX

Co plans more animal studies and aims to seek regulatory nod for human trials

As of last close, stock up ~3% over the past year